Bioavailability and Genotype - Clinical Research Informer

FDA Advisory Committee Recommends Use of Investigational Drug Maribavir (TAK-620) to Treat Post-Transplant Recipients with Cytomegalovirus (CMV) Infection and Disease Refractory to Treatment With or Without Resistance

The Pharma Data

OCTOBER 9, 2021

Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously to recommend use of maribavir (TAK-620) for the treatment of refractory cytomegalovirus (CMV) infection and disease with genotypic resistance to ganciclovir, valganciclovir, foscarnet or cidofovir in transplant recipients. About maribavir.

Drugs

Drugs Genotype Bioavailability Medicine

Innovative Companies Diving into The Neuro Market Ahead of 2021

The Pharma Data

DECEMBER 9, 2020

Vigil’s pipeline strategy is to target these diseases by combining a high-level understanding of microglia physiology, disease genotyping, and patient phenotyping to identify specific genetic variations associated with microglial dysfunction.

Marketing

Marketing In-Vivo Protein In-Vitro

Clinical study first step towards treating respiratory syncytial virus

Drug Discovery World

OCTOBER 18, 2022

Additionally, EDP-323 has favorable oral bioavailability with good plasma exposures across preclinical species and pharmacokinetic properties supporting once-daily oral dosing in humans. Senior Vice President and Chief Medical Officer of Enanta Pharmaceuticals.

In-Vitro

In-Vitro Genotype Bioavailability Clinical Trials

FDA Advisory Committee Recommends Use of Investigational Drug Maribavir (TAK-620) to Treat Post-Transplant Recipients with Cytomegalovirus (CMV) Infection and Disease Refractory to Treatment With or Without Resistance

Innovative Companies Diving into The Neuro Market Ahead of 2021

Clinical study first step towards treating respiratory syncytial virus

Stay Connected